DNA Constructs As shown in Figure S4B in Supplementary Material, pcDNA3.1-Flag-GSTP, pcDNA3.1-Flag-HMGB1, pcDNA3.1-Flag-GSTM, six GSTP phosphorylation mutants including pcDNA3.1-Flag-GSTP-S42A (in which serine-42 was mutated to alanine, a S42 non-phosphorylatable mutant), pcDNA3.1-Flag-GSTP-S42D (in which serine-42 was mutated to aspartate, a Ser42 constant-phosphomimetic mutant), pcDNA3.1-Flag-GSTP-S184A (in which serine-184 was mutated to alanine, a Ser184 non-phosphorylatable mutant), pcDNA3.1-Flag-GSTP-S184D (in which serine-184 was mutated to aspartate, a Ser184 constant-phosphomimetic mutant), pcDNA3.1-Flag-GSTP-Y198F (in which tyrosine-198 was mutated to phenylalanine, a Tyr198 non-phosphorylatable mutant) and pcDNA3.1-Flag-GSTP-Y198D (in which tyrosine-198 was mutated to aspartate, a Tyr198 constant-phosphomimetic mutant), pET28a-HMGB1, pET28a-GSTP(WT), pET28a-GSTP(S184A), pET28a-GSTP(S184D) were constructed by using molecular cloning technology

Interaction of luteolin, naringenin, and their sulfate and glucuronide conjugates with human serum albumin, cytochrome P450 (CYP2C9, CYP2C19, and CYP3A4) enzymes and organic anion transporting polypeptide (OATP1B1 and OATP2B1) transporters
Sample size was determined following Meads Rule [33]
The researchers administered 2.4 mg subcutaneous semaglutide (Wegovy, Novo Nordisk) once weekly to patients with obesity and moderate knee OA, who had at least moderate pain, and compared their outcomes with a placebo group over 68 weeks
They share the same receptor pathway, and doubling up dramatically increases the risk of severe gastrointestinal side effects without proportional benefit
Five percent of people account for nearly half of all health spending, driven by patients with three or more chronic conditions